Imatinib-treated Chronic Myeloid Leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Disclosures: MB reports grants from Novartis Farma, personal fees from Ariad Pharmaceuticals, and Amgen, outside the submitted work; MT reports personal fees from Novartis Pharma, Bristol-Myers Squibb, and ARIAD Pharmaceuticals, outside the submitted work; GB, EM, EC, LM, LS, LF, FDM, MK, GS, RF, and AA have nothing to disclose.

Contributions: M.B., G.B. and M.T. designed the research. M.B., G.B., E.M., E.C. and M.T. collected the data. L.M., L.S., L.F., F.D.M., M.K., G.S., R.F. and A.A. included patients, contributed data and commented on the manuscript. M.B. and M.T. analyzed, interpreted the data, and wrote the manuscript. All authors read and agreed to the final version of the manuscript.